Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBIS XLH observational study in adults with X-linked hypophosphatemia receiving burosumab
jRCT1050260075Suspended
- Sponsor
- Novo Nordisk
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of burosumab in X-linked hypophosphataemia (XLH), sponsored by Novo Nordisk. Primary endpoint: Average trough serum phosphate concentration. Started Jul 2026; status: suspended.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphataemia (XLH)
Beyond the preview
Go deeper on jRCT1050260075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050260075.